Physician profile
Mark Andolina
NPI 1346451051
$402,105.83
in general payments reported to CMS, 2019-2025
34 companies · $62K in 2025
The $62K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $15K · 2021: $30K · 2022: $62K · 2023: $68K · 2024: $120K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $220K · Travel and Lodging: $16K · Consulting Fee: $8,058 · Food and Beverage: $6,104 · Education: $46.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $220,007.21 |
| Travel and Lodging | $16,161.95 |
| Consulting Fee | $8,057.50 |
| Food and Beverage | $6,104.01 |
| Education | $46.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $161,599.60 | 2019-2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $142,616.44 | 2021-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $72,354.14 | 2019-2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $22,181.35 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Regeneron Pharmaceuticals, INC. | $2,141.75 | 2025 | Libtayo |
| Pfizer INC. | $134.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $122.73 | 2022-2025 | |
| Galvanize Therapeutics, INC | $116.19 | 2023 | Aliya System |
| Incyte Corporation | $106.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $89.23 | 2023-2024 | Enhertu, Calquence |
| Abbvie INC. | $58.25 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $57.67 | 2024-2025 | |
| Genentech USA, INC. | $53.44 | 2020-2023 | Venclexta, Phesgo |
| Seagen INC. | $36.14 | 2023 | Padcev |
| Astellas Pharma US INC | $32.06 | 2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $31.97 | 2024-2025 | Jemperli, Zejula |
| Celgene Corporation | $28.13 | 2023 | Pomalyst, Reblozyl |
| Lilly USA, LLC | $27.58 | 2022-2023 | Jaypirca, Verzenio |
| Genzyme Corporation | $27.14 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $26.95 | 2022 | |
| Puma Biotechnology, INC. | $26.27 | 2020 | |
| Eisai INC. | $24.27 | 2023 | |
| Servier Pharmaceuticals LLC | $22.38 | 2023 | |
| Immunocore Limited | $20.00 | 2024 | Kimmtrak |
| Amgen INC. | $19.32 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $19.01 | 2024 | Sancuso |
| Mirati Therapeutics, INC. | $18.60 | 2023 | Krazati |
| Sirtex Medical INC | $18.23 | 2025 | Sir-Spheres Microspheres |
| Ipsen Biopharmaceuticals, INC | $17.87 | 2019 | |
| Array Biopharma INC | $16.91 | 2025 | Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $16.58 | 2023 | Opdivo |
| Cti Biopharma Corp. | $16.18 | 2023 | Vonjo |
| Secura Bio, INC. | $15.54 | 2024 | Copiktra |
| Rigel Pharmaceuticals, INC. | $12.75 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Andolina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.